Crenolanib

GPTKB entity

Statements (58)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:activities inhibitor of FL T3 kinase
gptkbp:appointed_by oral tablet
gptkbp:approves gptkb:2014
gptkb:United_States
gptkbp:brand gptkb:Pralsetinib
gptkbp:class gptkb:Cloud_Computing_Service
gptkbp:clinical_trial gptkb:Ariad_Pharmaceuticals
gptkb:Europe
gptkb:Asia
gptkb:United_States
Phase 1
Phase 3
gptkbp:composed_of gptkb:chemical_compound
gptkbp:contraindication severe renal impairment
severe liver impairment
hypersensitivity to crenolanib
gptkbp:date 2015-01-15
gptkbp:discovered_by gptkb:Ariad_Pharmaceuticals
gptkbp:dissolved soluble in DMSO
slightly soluble in water
gptkbp:healthcare 2014-10-01
https://www.w3.org/2000/01/rdf-schema#label Crenolanib
gptkbp:ingredients C22 H24 Cl N5 O2 S
gptkbp:interacts_with CY P3 A4 inducers
CY P3 A4 inhibitors
QT prolonging agents
gptkbp:invention patented
gptkbp:is_atype_of L01 XX
gptkbp:is_used_for treatment of acute myeloid leukemia
gptkbp:manager oral
gptkbp:marketed_as gptkb:Ariad_Pharmaceuticals
gptkbp:pharmacokinetics oral bioavailability
FL T3 inhibition
gptkbp:population adults with AML
gptkbp:produced_by clinical trials
gptkbp:project Phase 2
gptkbp:provides_information_on daily dosing
gptkbp:research_areas various cancer research centers
gptkbp:research_focus oncology
gptkbp:side_effect gptkb:fandom
fatigue
nausea
diarrhea
liver enzyme elevation
thrombocytopenia
infection risk
cardiac arrhythmias
bleeding complications
gptkbp:targets gptkb:healthcare_organization
FL T3 receptor
gptkbp:treatment improved survival rates
reduced relapse rates
increased complete response rates
gptkbp:type_of 1000370-80-0
gptkbp:weight 429.97 g/mol
gptkbp:bfsParent gptkb:Genzyme_Genetics
gptkbp:bfsLayer 5